Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Brexanolone Lifting Outcomes Of Moms

ClinicalTrials.gov ID: NCT07822321

Public ClinicalTrials.gov record NCT07822321. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause

Study identification

NCT ID
NCT07822321
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Lipocine Inc.
Industry
Enrollment
120 participants

Conditions and interventions

Eligibility (public fields only)

Age range
15 Years to 45 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2026
Primary completion
Jul 31, 2027
Completion
Aug 31, 2027
Last update posted
Sep 15, 2026

2026 – 2027

United States locations

U.S. sites
16
U.S. states
13
U.S. cities
16
Facility City State ZIP Site status
Lipocine Investigational Site Tucson Arizona 85715 Recruiting
Lipocine Investigational Site Canoga Park California 91304 Recruiting
Lipocine Investigational Site Walnut Creek California 94596 Recruiting
Lipocine Investigational Site Aurora Colorado 80045 Recruiting
Lipocine Investigational Site Decatur Georgia 30030 Recruiting
Lipocine Investigational Site Idaho Falls Idaho 83402 Recruiting
Lipocine Investigational Site Chicago Illinois 60641 Recruiting
Lipocine Investigational Site New Orleans Louisiana 70115 Recruiting
Lipocine Investigational Site Las Vegas Nevada 89119 Recruiting
Lipocine Investigational Site Princeton New Jersey 08540 Recruiting
Lipocine Investigational Site Manhattan New York 10036 Recruiting
Lipocine Investigational Site Chapel Hill North Carolina 27514 Recruiting
Lipocine Investigational Site Plano Texas 75093 Recruiting
Lipocine Investigational Site Richardson Texas 75080 Recruiting
Lipocine Investigational Site Clinton Utah 84105 Recruiting
Lipocine Investigational Site Orem Utah 84058 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07822321, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2026 · Synced Sep 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07822321 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →